Featured Intelligence

When a genetic testing company goes bankrupt, its most valuable holding is not its lab equipment. It is the genetic profiles of everyone who ever sent in a saliva sample. That is exactly what played out with 23andMe, whose bankruptcy

For years, AI drug discovery has been judged mostly on promises: faster timelines, cheaper pipelines, smarter molecule design. This year, one of those promises finally reached a stage where it has to prove itself against real patients. Insilico Medicine'

A large independent review of fish oil supplements published this year offers a useful snapshot of where supplement quality verification actually stands. Consumer Reports tested more than fifty samples across twenty-one products for omega-3 content, rancidity, and a

The word bioprinting tends to conjure images of a printed kidney or lung ready for transplant, but the actual human clinical progress right now looks much smaller and more specific. A company called 3DBio Therapeutics ran the first FDA-authorized

Cord blood banking has quietly become a large, established industry: nearly five million units are stored worldwide, most in private family banks, with roughly a million more sitting in public registries available for matched patients. More than forty thousand cord

A new tariff structure aimed at pulling drug manufacturing back onto domestic soil hits a major compliance deadline this week. Fourteen major manufacturers, including Eli Lilly, AbbVie, AstraZeneca, Pfizer, and Merck, have pledged a combined figure well into the hundreds

The Alzheimer's Association has launched a large, multi-year trial testing something that sounds almost too straightforward: combining a proven lifestyle program with a metabolism-targeting drug to see whether the two together meaningfully lower the risk of

Consumer wearables spent a decade counting steps and heart rate. That era is ending. Dexcom's over-the-counter glucose sensor, once limited to adults, has recently been cleared for children as well, engineers at UC San Diego built

For years, cellular reprogramming, the idea of resetting an aged cell's chemical instructions back toward a younger-acting state, lived almost entirely in mouse studies and funding announcements. That changed this year. Life Biosciences began dosing human patients